World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
80
Citations
29140
World Ranking
16961
National Ranking
568

Overview

Ian D. Davis is affiliated with Monash University in Australia. Their research primarily focuses on the field of Medicine, with significant specialization in Pulmonary and Respiratory Medicine, Surgery, Oncology, Radiology, Nuclear Medicine and Imaging, and Cancer Research. This multidisciplinary approach encompasses various aspects of cancer treatment and related medical fields.

The main topics covered in their research include:

  • Prostate Cancer Treatment and Research
  • Bladder and Urothelial Cancer Treatments
  • Radiopharmaceutical Chemistry and Applications
  • Cancer Immunotherapy and Biomarkers
  • Prostate Cancer Diagnosis and Treatment
  • Cancer, Lipids, and Metabolism
  • Renal Cell Carcinoma Treatment

Ian D. Davis has contributed to multiple highly cited papers in well-known medical journals. Selected recent publications are:

  • [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial (2021), The Lancet
  • Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial (2020), The Lancet
  • Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019 (2020), European Urology
  • Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial (2020), The Lancet Oncology
  • Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial (2022), The Lancet Oncology

Their frequent co-authors include:

  • Martin R. Stockler
  • Andrew Martin
  • Anthony M. Joshua
  • Michael S. Hofman
  • Shahneen Sandhu

The venues where Ian D. Davis most frequently publishes research are:

  • Journal of Clinical Oncology
  • European Urology
  • Annals of Oncology
  • British Journal of Urology
  • The Lancet Oncology

Best Publications

  • Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

    Tomasz M Beer;Andrew J Armstrong;Dana E Rathkopf;Yohann Loriot

  • Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial

    Cora N. Sternberg;Ian D. Davis;Jozef Mardiak;Cezary Szczylik

  • Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

    Ian D. Davis;Andrew J. Martin;Martin R. Stockler;Stephen Begbie

  • [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial

    Michael S Hofman;Louise Emmett;Shahneen Sandhu;Amir Iravani

  • Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial.

    Matthew D. Galsky;José Ángel Arranz Arija;Aristotelis Bamias;Ian D. Davis

  • Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017

    Silke Gillessen;Gerhardt Attard;Tomasz M Beer;Himisha Beltran

  • Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans.

    Ian D. Davis;Weisan Chen;Heather Jackson;Phillip Parente;Phillip Parente

  • A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update

    Cora N. Sternberg;Robert E. Hawkins;John Wagstaff;Pamela Salman

  • Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

    Thomas Powles;Michiel S van der Heijden;Daniel Castellano;Matthew D Galsky

  • Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group.

    M E Gleave;M Elhilali;Y Fradet;I Davis

  • Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015

    S Gillessen;A Omlin;G Attard;J S de Bono

  • Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019[Formula presented]

    Silke Gillessen;Gerhardt Attard;Tomasz M. Beer;Himisha Beltran

  • Efficacy and Safety of Pazopanib in Patients With Metastatic Renal Cell Carcinoma

    Thomas E. Hutson;Ian D. Davis;Jean-Pascal H. Machiels;Paul L. De Souza

  • Tumor antigen expression in melanoma varies according to antigen and stage

    Catherine Barrow;Judy Browning;Duncan MacGregor;Ian D. Davis

  • Breast and prostate cancer: more similar than different.

    Gail Petuna Risbridger;Ian D Davis;Stephen N Birrell;Wayne D Tilley

  • Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial

    Robert John Motzer;Camillo Porta;Nicholas J Vogelzang;Cora N Sternberg

  • Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial.

    Andrew Kneebone;Andrew Kneebone;Carol Fraser-Browne;Gillian M Duchesne;Gillian M Duchesne;Richard Fisher

  • Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery

    Max Schnurr;Qiyuan Chen;Qiyuan Chen;Amanda Shin;Amanda Shin;Weisan Chen;Weisan Chen

  • CLINICAL ROLE OF F-18 FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY FOR DETECTION AND MANAGEMENT OF RENAL CELL CARCINOMA

    Shakher Ramdave;Gwynne W. Thomas;Salvatore U. Berlangieri;Damien M. Bolton

  • The regulatory T cell-associated transcription factor FoxP3 is expressed by tumor cells.

    Lisa M Ebert;Bee Shin Tan;Judy Browning;Suzanne Svobodova

Frequent Co-Authors

Jonathan Cebon
Jonathan Cebon La Trobe University
Andrew M. Scott
Andrew M. Scott La Trobe University
Nathan Lawrentschuk
Nathan Lawrentschuk University of Melbourne
Weisan Chen
Weisan Chen La Trobe University
Andrew J. Martin
Andrew J. Martin University of New South Wales
Eugene Maraskovsky
Eugene Maraskovsky CSL (United Kingdom)
Graham G. Giles
Graham G. Giles University of Melbourne
Grant A. McArthur
Grant A. McArthur Peter MacCallum Cancer Centre
Declan G. Murphy
Declan G. Murphy King's College London
Lloyd J. Old
Lloyd J. Old Ludwig Cancer Research

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine doesn’t always mean pursuing a traditional MD. There are a variety of online degrees and alternative career pathways that offer rewarding opportunities in healthcare.

For those with a non-nursing bachelor’s degree, non nursing bachelor's to msn online programs allow a fast track into advanced nursing without repeating undergraduate studies. These flexible options can accelerate your transition to leadership roles within the medical field.

If you’re concerned about meeting rigorous admission standards, consider easy nursing programs to get into. Some programs focus on holistic admission criteria, making the nursing profession more accessible for a wider range of backgrounds and experiences.

For those drawn to healthcare administration, online medical billing and coding with financial aid programs offer a practical route. These programs can launch your career in medical records, billing, and insurance—roles that are in high demand.

Lastly, aspiring nurses who want to avoid standardized admissions testing might explore nursing schools that don't require teas test. This pathway can help ease the entry process, allowing you to focus on your studies and future career.

Best Scientists Citing Ian D. Davis

Trending Scientists